In a groundbreaking head-to-head trial funded by Eli Lilly, Zepbound outperformed Wegovy in weight loss efficacy. Participants on Zepbound shed an average of 20.2% of their body weight, compared to 13.7% on Wegovy—a 47% greater reduction, according to Lilly’s announcement. The trial, which included 751 adults, marks the first randomized comparison of the two leading GLP-1 drugs.
Keep Reading
Add A Comment